Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morris, T. J.
Right arrow Articles by Buchwald, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, T. J.
Right arrow Articles by Buchwald, H.

Annals of Surgical Oncology, Vol 2, Issue 3 266-274, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth

T. J. Morris, S. L. Palm, L. L. Furcht and H. Buchwald
Department of Surgery, University of Minnesota, Minneapolis 55455, USA.

BACKGROUND: Cholesterol is essential for cell viability and growth. Interference with the cholesterol biosynthetic pathway with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (e.g., lovastatin) may preferentially slow malignant cell growth and offer a new approach to cancer chemotherapy. To test this hypothesis, we evaluated the effect of lovastatin alone, and as an adjuvant chemotherapeutic agent, on the growth and function of hepatoma tissue culture-4 (HTC-4) cells. METHODS: HTC-4 cells were treated with lovastatin at concentrations of 1, 3, 5, and 10 microM, with mitomycin-C at concentrations of 10, 25, 50, and 100 nM, or with combinations of the two drugs. Cell growth was evaluated by daily cell counts and substrate adhesion to fibronectin. RESULTS: Lovastatin alone slowed HTC-4 cell growth at concentrations as low as 1 microM (p < 0.01). Mitomycin-C alone slowed HTC-4 cell growth at concentrations of 25 nM and above (p < 0.01). Lovastatin added to mitomycin-C-treated cells resulted in a significant adjuvant effect, with cell growth slowed by an additional 20-30% by 1 microM lovastatin and by an additional 43-63% by 5 microM lovastatin, compared to mitomycin-C alone (p < 0.01). Lovastatin-treated cells also exhibited decreased adherence to substrate (p < 0.05). CONCLUSIONS: Lovastatin is effective alone and as an adjuvant to mitomycin-C in slowing the growth of HTC-4 cells. These in vitro results support further investigation of lovastatin as an adjuvant chemotherapeutic agent in animal models.


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
B. Agarwal, B. Halmos, A. S. Feoktistov, P. Protiva, W. G. Ramey, M. Chen, C. Pothoulakis, J.T. Lamont, and P. R. Holt
Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells
Carcinogenesis, March 1, 2002; 23(3): 521 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
K. M. Anderson and J. E. Harris
Selected Features of Nonendocrine Pancreatic Cancer
Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Feleszko
Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
Clin. Cancer Res., March 1, 2000; 6(3): 1198 - 1199.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. B. RUBINS, T. GREATENS, R. A. KRATZKE, A. T. TAN, V. A. POLUNOVSKY, and P. BITTERMAN
Lovastatin Induces Apoptosis in Malignant Mesothelioma Cells
Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1616 - 1622.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.